Core Viewpoint - Immatics N.V. has announced an underwritten offering of 12,500,000 ordinary shares at a price of $10.00 per share, aiming to raise gross proceeds of $125 million before expenses [1]. Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, a target expressed in over 50 types of cancer. The company boasts a robust clinical pipeline and the broadest PRAME franchise, which includes TCR T-cell therapies and TCR bispecifics [4]. Offering Details - The offering is expected to close on December 8, 2025, subject to customary closing conditions [1]. - Jefferies, Leerink Partners, and Cantor are acting as joint book-running managers for the offering [2]. - A registration statement for the securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on April 3, 2025 [3].

Core Points - Ocular Therapeutix, Inc. announced an underwritten offering of 37,909,018 shares of common stock at a price of $12.53 per share, aiming for gross proceeds of approximately $475.0 million [1] - The offering is expected to close on or about October 1, 2025, pending customary closing conditions [1] Use of Proceeds - The net proceeds from the offering will be used to fund an open-label extension study for AXPAXLI™ in patients with wet age-related macular degeneration (wet AMD) [3] - Funds will also support Phase 3 clinical trials of AXPAXLI for treating non-proliferative diabetic retinopathy (NPDR), infrastructure investments, pre-commercialization activities, and general corporate purposes [3] Offering Details - The offering is conducted under an automatically effective shelf registration statement on Form S-3 filed with the SEC [4] - Joint book-running managers for the offering include BofA Securities, TD Cowen, and Piper Sandler & Co., with Baird and Raymond James as lead managers [2] Company Overview - Ocular Therapeutix is focused on redefining the retina experience and has an investigational product candidate, AXPAXLI, currently in Phase 3 trials for wet AMD and NPDR [6] - The company also markets DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain, and is developing OTX-TIC for open-angle glaucoma [7]